MX2021001711A - Proteínas biespecíficas modificadas. - Google Patents

Proteínas biespecíficas modificadas.

Info

Publication number
MX2021001711A
MX2021001711A MX2021001711A MX2021001711A MX2021001711A MX 2021001711 A MX2021001711 A MX 2021001711A MX 2021001711 A MX2021001711 A MX 2021001711A MX 2021001711 A MX2021001711 A MX 2021001711A MX 2021001711 A MX2021001711 A MX 2021001711A
Authority
MX
Mexico
Prior art keywords
bispecific proteins
engineered bispecific
engineered
proteins
antigens
Prior art date
Application number
MX2021001711A
Other languages
English (en)
Spanish (es)
Inventor
Gunasekaran Kannan
Adam P Silverman
Do Jin Kim
Pascal Sanchez
Hai L Tran
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MX2021001711A publication Critical patent/MX2021001711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021001711A 2018-08-16 2019-08-15 Proteínas biespecíficas modificadas. MX2021001711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862765095P 2018-08-16 2018-08-16
PCT/US2019/046705 WO2020037150A2 (en) 2018-08-16 2019-08-15 Engineered bispecific proteins

Publications (1)

Publication Number Publication Date
MX2021001711A true MX2021001711A (es) 2021-05-27

Family

ID=69525976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001711A MX2021001711A (es) 2018-08-16 2019-08-15 Proteínas biespecíficas modificadas.

Country Status (14)

Country Link
US (1) US20220017634A1 (https=)
EP (1) EP3850007A4 (https=)
JP (1) JP7397063B2 (https=)
KR (1) KR20210064199A (https=)
CN (1) CN112839955A (https=)
AU (1) AU2019320803A1 (https=)
BR (1) BR112021002730A2 (https=)
CA (1) CA3109763A1 (https=)
EA (1) EA202190542A1 (https=)
IL (1) IL280882A (https=)
MA (1) MA53616A (https=)
MX (1) MX2021001711A (https=)
SG (1) SG11202101273VA (https=)
WO (1) WO2020037150A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
BR112021015656A2 (pt) 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
EP4229192A1 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
WO2023038803A2 (en) * 2021-08-25 2023-03-16 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
WO2023085779A1 (ko) * 2021-11-09 2023-05-19 한양대학교 산학협력단 Fc 변이체를 포함하는 이종이합체 및 이의 제조방법
JP2025503437A (ja) * 2021-12-17 2025-02-04 デナリ セラピューティクス インコーポレイテッド ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド
US12011489B2 (en) 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease
KR20250058123A (ko) 2022-07-29 2025-04-29 리제너론 파마슈티칼스 인코포레이티드 항-TfR:페이로드 융합 및 이의 사용 방법
CA3263388A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
CN118221803A (zh) * 2022-12-19 2024-06-21 深圳科兴药业有限公司 异源二聚体Fc融合蛋白及其用途
IL326018A (en) 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
SG11201404751UA (en) * 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
EP3594240B1 (en) * 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
CA2944402A1 (en) * 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
HUE057952T2 (hu) * 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
CN107531788B (zh) * 2015-06-24 2022-06-21 豪夫迈·罗氏有限公司 对her2和血脑屏障受体特异性的三特异性抗体及使用方法
EA039366B1 (ru) * 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
CN110506055A (zh) * 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
WO2018237338A1 (en) * 2017-06-23 2018-12-27 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
CR20200129A (es) * 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
WO2019094576A1 (en) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Bace-tau bispecific antibodies
WO2019094608A1 (en) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
TW201934573A (zh) * 2018-01-10 2019-09-01 美商戴納立製藥公司 轉鐵蛋白受體結合性多肽及其用途
WO2019246071A1 (en) * 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin

Also Published As

Publication number Publication date
CN112839955A (zh) 2021-05-25
SG11202101273VA (en) 2021-03-30
BR112021002730A2 (pt) 2021-08-10
CA3109763A1 (en) 2020-02-20
WO2020037150A2 (en) 2020-02-20
US20220017634A1 (en) 2022-01-20
EA202190542A1 (ru) 2021-09-07
EP3850007A4 (en) 2022-08-10
IL280882A (en) 2021-04-29
MA53616A (fr) 2022-05-04
JP2021533779A (ja) 2021-12-09
AU2019320803A1 (en) 2021-03-11
EP3850007A2 (en) 2021-07-21
WO2020037150A3 (en) 2020-10-15
JP7397063B2 (ja) 2023-12-12
KR20210064199A (ko) 2021-06-02

Similar Documents

Publication Publication Date Title
MX2021001711A (es) Proteínas biespecíficas modificadas.
IL280673A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
PH12020550408A1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
WO2019005637A3 (en) Multi-specific antibodies and methods of making and using thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
AU2014232501C1 (en) Heterodimeric proteins
AU2018256592A1 (en) Binding proteins comprising at least two repeat domains against HER2
MX2022015823A (es) Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
IL280618A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
HK1207398A1 (en) Cd3 binding polypeptides
NZ720765A (en) Antibodies and methods of use
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
NZ740474A (en) Antigen receptors and uses thereof
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2023009715A (es) Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo.
EP4268848A3 (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof